App-Quantinova.ai

New frontiers in second-line treatment of Glioblastoma: Re-irradiation in combination with FotemustineA single institution experience.

Alicia Marin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

5-aminolevulinic acid hydrochloride

Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study.

Estela Pineda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapyA multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013.

Carmen Balana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Breast-GPA and type of treatment predictors of survival in brain metastasis patients.

Jenniffer Linares Aceituno - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

Personalized gene expression profiling-guided (MAGE) therapy in resistant sarcomas. Preliminary data.

Manuel Sureda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Sarcoma

N/A

Implication of MODEL of financing clinical research in breast cancer during the past two decades.

Yolanda Jerez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Thrombosis in a population of phase I trial patients.

Alan D. Smith - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.

Mariane Sousa Fontes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

2-OHOA

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Kimberly Blackwell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Analysis of the HLA-I genotypes in patients with solid tumours who were treated with anti-HER therapy.

Javier Lopez-Gonzalez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.

Ivan Victoria - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Ipilimumab

Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.

Robert J. Mayer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

TAS102

Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA).

Carles Pericay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Aflibercept

Improving metachronous cancer risk assessment using clinicopathological information in colorectal cancer patients.

Takaharu Kato - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value.

Gil Raga Mireia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy.

Joana Vidal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.

Antonio Cubillo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Capecitabine-oxaliplatin (CAPOX) prior to chemoradiotherapy (CRT) and surgery in magnetic resonance imaging (MRI)-defined poor-risk rectal carcinoma (PRRC): A center experience.

Isabel Busquier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine + Oxaliplatin

Outcomes of elderly patients receiving neoadjuvant chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer in a retrospective cohort.

Pablo Reguera Puertas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA).

Guillermo Alfonso Quintero Aldana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

panitumumab

Filters

24923 Abstracts